Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
prinomastat · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| cisplatin | DRUG | - |
| gemcitabine hydrochloride | DRUG | - |
| prinomastat | DRUG | - |
| temozolomide | DRUG | - |
DISEASE CHARACTERISTICS: Stage IV or recurrent or T4 lesion non-small cell lung cancer Measurable or evaluable disease No brain metastases PATIENT CHARACTERISTICS: Age: 18 and over Performance status: WHO 0-1 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: ...
Top 20 of 76 competitors
Prinomastat is an investigational small molecule being studied for the treatment of brain and central nervous system tumors, specifically glioblastoma multiforme, and lung cancer, specifically non-small cell lung cancer. It is being developed by Pfizer, Inc. and is currently in clinical trials for these oncology indications.
Prinomastat is a small molecule being studied in oncology. Its specific molecular target has not been disclosed in the available clinical trial information. The drug is being investigated for its potential role in treating brain and central nervous system tumors and lung cancer.
Prinomastat is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with certain types of cancer.
Prinomastat is in Phase 2 clinical development. It has been studied in a completed Phase 2 trial for brain and central nervous system tumors. Prinomastat is investigational and has not been approved by regulatory authorities for any use.
Prinomastat has been evaluated in clinical trials registered under NCT00004199 and NCT00004200. NCT00004199 studied prinomastat with combination chemotherapy in patients with metastatic or recurrent non-small cell lung cancer. NCT00004200 studied prinomastat plus temozolomide following radiation therapy in patients with newly diagnosed glioblastoma multiforme.
Prinomastat is also known by the code name AG3340. It is an investigational small molecule being developed by Pfizer, Inc. for the treatment of brain and central nervous system tumors and lung cancer. The drug is currently in Phase 2 clinical development.